Previous 10 | Next 10 |
NEWARK, Calif. , May 12, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of...
NEWARK, Calif. , May 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares of commo...
Image source: The Motley Fool. Protagonist Therapeutics, Inc. Common Stock (NASDAQ: PTGX) Q1 2020 Earnings Call May 07, 2020 , 5:00 p.m. ET Operator Continue reading
Shares of Protagonist Therapeutics (NASDAQ: PTGX) -- a clinical-stage biopharmaceutical company -- are up by 111.6% as of 12:34 p.m. EDT on Friday. Protagonist Therapeutics released its fiscal first-quarter earnings report after the market closed on Thursday, and the company announced some e...
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +74% . More news on: Protagonist Therapeutics, Inc., Everspin Technologies, Inc., American Axle & Manufacturing Holdings, Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Protagonist Therapeutics (NASDAQ: PTGX ) is up 16% premarket on light volume on the heels of its announcement that it has chosen polycythemia vera , a type of blood cancer in which the bone marrow produces too many red blood cells, as the first indicati...
Protagonist (NASDAQ: PTGX ): Q1 GAAP EPS of -$0.72 misses by $0.03 . Revenue of $3.65M (+134.0% Y/Y) beats by $2.17M . Press Release More news on: Protagonist Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news
NEWARK, Calif. , May 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the first quarter ended March 31, 2020 , and provided an update on clinical development programs. "Based on the highly promising and consi...
NEWARK, Calif. , May 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera. The current results demonstrate that treatment with PTG-300 at individualized doses ran...
NEWARK, Calif. , May 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020 . Protagonist management will host a conference call to provide a corporate and R&D upd...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...